Prolia, a bone-building osteoporosis medication previously indicated only to women, has recently been approved by the United States Food and Drug Administration with a new indication as a drug therapy that may help promote increased bone mass in men who stand at a greater risk of osteoporotic fractures.

Manufactured by the pharmaceutical firm Amgen Inc. (AMGN), Prolia, is a lab-produced antibody that slows down not only the bone breakdown part of the bone cycle process, but also impedes the entire bone remodeling process itself.  Otherwise known by its generic equivalent denosumab, the intravenous bone drug is frequently prescribed to postmenopausal women who face a higher fracture risk, patients who may have not found therapeutic benefits from other osteoporosis therapies, and people who may have lower tolerance to other osteoporosis medications including anabolic drugs and bisphosphonates.

Sources:

equities.com/news/headline-story?dt=2012-09-22&val=509579&cat=hcare

webmd.com/osteoporosis/news/20100602/fda-approves-prolia-for-high-risk-osteoporosis